In fact, previous research has shown that small GR antagonist molecules that are active in the liver can successfully ameliorate metabolic syndrome in rats51, suggesting that modulation of the GR pathway could help reduce known metabolic liver pathology in SMA12,19. This evidence concerns the gene NR3C1 and metabolic syndrome.